QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$261.22
-4.93 (-1.85%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$260.95
▼
$267.25
50-Day Range
$256.56
▼
$292.34
52-Week Range
$187.16
▼
$311.88
Volume
530,145 shs
Average Volume
1.02 million shs
Market Capitalization
$37.74 billion
P/E Ratio
12.48
Dividend Yield
N/A
Price Target
$315.38

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
20.7% Upside
$315.38 Price Target
Short Interest
Healthy
1.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.47mentions of Biogen in the last 14 days
Based on 29 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.51%
From $15.53 to $16.23 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

109th out of 983 stocks

Biological Products, Except Diagnostic Industry

18th out of 163 stocks

See Top Rated MarketRank™ Stocks Here

BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

March 14, 2023 | marketbeat.com
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3 (BIIB)
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,
February 22, 2023 | marketbeat.com
3 More Mid-Cap Biotechs The Street Sees Doubling (BIIB)
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
March 22, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
March 22, 2023 | cnbc.com
FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease
March 22, 2023 | seekingalpha.com
Biogen ALS drug tofersen earns mixed voting by FDA advisory panel
March 22, 2023 | finance.yahoo.com
UPDATE 1-US FDA panel votes against effectiveness of Biogen's ALS drug
March 22, 2023 | americanbankingnews.com
Q1 2023 Earnings Forecast for Biogen Inc. Issued By William Blair (NASDAQ:BIIB)
March 21, 2023 | finance.yahoo.com
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
March 22, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 20, 2023 | cnbc.com
FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease
March 20, 2023 | finance.yahoo.com
UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval
March 20, 2023 | finance.yahoo.com
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
March 20, 2023 | americanbankingnews.com
Head-To-Head Comparison: Biogen (NASDAQ:BIIB) versus Omega Therapeutics (NASDAQ:OMGA)
March 19, 2023 | finance.yahoo.com
Should You Buy Biogen Before a Big July Decision?
March 19, 2023 | americanbankingnews.com
Biogen (NASDAQ:BIIB) Research Coverage Started at StockNews.com
March 17, 2023 | finance.yahoo.com
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
March 17, 2023 | finance.yahoo.com
Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 27% Undervaluation?
March 16, 2023 | finance.yahoo.com
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023 | benzinga.com
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023 | finance.yahoo.com
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
March 16, 2023 | finance.yahoo.com
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
March 16, 2023 | americanbankingnews.com
Biogen Inc. (NASDAQ:BIIB) Short Interest Up 8.2% in February
March 15, 2023 | americanbankingnews.com
Biogen (NASDAQ:BIIB) Price Target Raised to $350.00 at Royal Bank of Canada
March 14, 2023 | finance.yahoo.com
Veterans Health to cover Eisai, Biogen’s new Alzheimer’s drug
March 14, 2023 | finance.yahoo.com
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
March 14, 2023 | finance.yahoo.com
The VA Will Pay for Leqembi. It’s a Step in Right Direction for Biogen.
March 14, 2023 | finance.yahoo.com
Biogen Appoints Chuck Triano as Head of Investor Relations
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
2/15/2023
Today
3/22/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
CIK
875045
Web
www.biogen.com
Phone
(617) 679-2000
Fax
617-679-2617
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$315.38
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$225.00
Forecasted Upside/Downside
+19.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
26 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$20.93
Trailing P/E Ratio
12.65
Forward P/E Ratio
17.04
P/E Growth
2.22
Net Income
$3.05 billion
Net Margins
29.95%
Pretax Margin
35.31%
Return on Equity
20.96%
Return on Assets
10.52%

Debt

Debt-to-Equity Ratio
0.47
Current Ratio
2.99
Quick Ratio
2.58

Sales & Book Value

Annual Sales
$10.17 billion
Price / Sales
3.76
Cash Flow
$21.64 per share
Price / Cash Flow
12.23
Book Value
$92.97 per share
Price / Book
2.85

Miscellaneous

Outstanding Shares
144,490,000
Free Float
143,547,000
Market Cap
$38.25 billion
Optionable
Optionable
Beta
0.19

Social Links


Key Executives

  • Christopher A. Viehbacher
    President, Chief Executive Officer & Director
  • Nicole Murphy
    Head-Pharmaceutical Operations & Technology
  • Michael R. McDonnell
    Chief Financial Officer & Executive Vice President
  • Mahalakshmi Radhakrishnan
    Chief Medical Officer & Group Senior VP
  • Priya Singhal
    Executive VP, Head-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 7 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

26 analysts have issued 1-year price targets for Biogen's stock. Their BIIB share price forecasts range from $225.00 to $370.00. On average, they predict the company's stock price to reach $315.38 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the beginning of the year. Since then, BIIB shares have decreased by 4.5% and is now trading at $264.50.
View the best growth stocks for 2023 here.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,850,000 shares, an increase of 8.2% from the February 13th total of 1,710,000 shares. Based on an average trading volume of 1,050,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.3% of the shares of the stock are sold short.
View Biogen's Short Interest.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our BIIB earnings forecast.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its earnings results on Wednesday, February, 15th. The biotechnology company reported $4.05 EPS for the quarter, beating the consensus estimate of $3.48 by $0.57. The biotechnology company earned $2.54 billion during the quarter, compared to analysts' expectations of $2.44 billion. Biogen had a net margin of 29.95% and a trailing twelve-month return on equity of 20.96%. The company's revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.39 earnings per share.
Read the conference call transcript.

What ETFs hold Biogen's stock?

ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), Psyk Etf (PSYK), iShares Neuroscience and Healthcare ETF (IBRN), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and Invesco Dynamic Pharmaceuticals ETF (PJP).

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided earnings per share guidance of $15.00-$16.00 for the period, compared to the consensus earnings per share estimate of $15.72. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (2.32%), Deutsche Bank AG (1.29%), Clearbridge Investments LLC (1.25%), Morgan Stanley (0.99%), Price T Rowe Associates Inc. MD (0.97%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos and Susan H Alexander.
View institutional ownership trends.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $264.50.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $38.22 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $20.93 on an earnings per share basis.

How many employees does Biogen have?

The company employs 8,725 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 3/22/2023 by MarketBeat.com Staff